Abstract:Chordoma is a rare bone sarcoma of the skull and spine with notochordal origins and an incidence of approximately 1 in every 1,000,000 people. Most chordomas (95%) are pathologically classified as conventional type and generally affect adults. Other chordoma subtypes include dedifferentiated and poorly differentiated with the latter being more common in pediatric patients and both being more aggressive with higher propensity for metastasis than conventional chordomas. Depending on the subtype, local recurrence and metastasis occurs in ~40-80% and ~5-40% of patients, respectively. Due to the rarity of this cancer, the understanding of primary and metastatic chordoma and its microenvironment is poor. Consequently, there are currently no standard therapies for recurrent or metastatic chordomas and 10-year survival rates remain around 30%. The tumor microenvironment (TME), a cellular ecosystem composed of nonmalignant cells that can promote tumor development and progression, offers a promising perspective that could yield novel insights into metastatic chordoma. Stromal and immune cells play key roles in tumor initiation, dissemination, metastasis, and therapeutic response. We hypothesize that the progression of cancer is intimately linked to the characteristics of immune and myeloid populations within the TME. Despite significant advances in the understanding of the genomic landscape of chordoma, the complex cellular milieu of the chordoma TME and its contribution to tumor progression remains unclear. To understand the prevalence and diversity of stromal and immune cells within the chordoma TME, we are utilizing multiplex immunofluorescence on a tissue microarray of chordomas (n=~30). Our preliminary findings show that tumor cell (brachyury+) contribution to the TME is highly heterogenous ranging from 2-88% (SD = 20.0, avg = 30%). Further, stromal cells (aSMA+) are the predominant cell type, comprised ~40% of the TME (SD = 19, 8-78%) whereas CD11b+ myeloid cells were rare contributing only to ~0.15% (SD = 0.39, 0-1.6%) of the cellular milieu in the chordoma TME. These results indicate a high degree of heterogeneity in stromal and myeloid cell populations between chordoma tumors and further our understanding of the spatial relationship between TME populations and tumor cells. Ongoing studies will include stromal cell subtyping (pericytes, endothelial cells, etc) and investigation of other immune populations including T cells and macrophages by multiplex immunofluorescence. Additionally, these immune- and stromal-rich regions will serve as regions of interest for future spatial transcriptomics studies. Further analysis of stromal and immune subsets within the TME of chordoma could reveal insights into mechanisms of metastasis and tumor progression, with the hope for additional treatment options to effectively re-educate the TME to eliminate tumor cells as well as identify key tumorigenic cell populations. Citation Format: Kailey Jackett, Miranda Sowder, Liny John, Ignatius Hazelwood, Rosandra Kaplan. Characterizing the key stromal and immune players in the microenvironment of primary and metastatic chordoma [abstract]. In: Proceedings of the AACR Special Conference: Cancer Metastasis; 2022 Nov 14-17; Portland, OR. Philadelphia (PA): AACR; Cancer Res 2022;83(2 Suppl_2) nr B017.

Expression of EGFR, C-Met and HER2/neu in Chordoma and Other Cancers

Egfr and Her2 Expression in Primary Cervical Cancers and Corresponding Lymph Node Metastases: Implications for Targeted Radiotherapy

Complete regression of a multicystic dysplastic kidney in the setting of renal crossed fused ectopia

Deficiency of PTEN and CDKN2A Tumor-Suppressor Genes in Conventional and Chondroid Chordomas: Molecular Characteristics and Clinical Relevance

Prognostic Significance of Cyclin E1 Expression in Patients with Chordoma: A Clinicopathological and Immunohistochemical Study.

EGFR, HER2, and HER3 Expression in Laryngeal Primary Tumors and Corresponding Metastases

PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment

Epidermal Growth Factor Receptor and Human Epidermal Growth Receptor 2 Expression in Parotid Mucoepidermoid Carcinoma: Possible Implications for Targeted Therapy.

CMTM3 Suppresses Chordoma Progress Through EGFR/STAT3 Regulated EMT and TP53 Signaling Pathway

Molecular Targeted Therapy in the Treatment of Chordoma: A Systematic Review

B7-H3 as a Target for CAR-T Cell Therapy in Skull Base Chordoma

Hypoxic Upregulation of IER2 Increases Paracrine GMFG Signaling of Endoplasmic Reticulum Stress‐CAF to Promote Chordoma Progression via Targeting ITGB1

Differential Proteomic Profiling of Chordomas and Analysis of Prognostic Factors

Clinical-proteomic classification and precision treatment strategy of chordoma

Abstract B017: Characterizing the key stromal and immune players in the microenvironment of primary and metastatic chordoma

Gene expression profiling identifies two chordoma subtypes associated with distinct molecular mechanisms and clinical outcomes

Chordoma cancer stem cell subpopulation characterization may guide targeted immunotherapy approaches to reduce disease recurrence

1228 Comprehensive T-cell Profiling in Chordomas: Single-cell RNA-Seq and TCR Profiling Analysis Uncover Antitumor and Exhaustion Phenotypes for Targeted Immunotherapies

Single-cell transcriptome profiling reveals intra-tumoral heterogeneity in human chordomas

Analysis of Clinicopathologic Features and Immunophenotype in 55 Patients with Chordoma

Rationale for the Advancement of PI3K Pathway Inhibitors for Personalized Chordoma Therapy